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Biomarkers for Sepsis
S. LaRosa
Rhode Island Hospital, Providence, USA
Manifestations of the Systemic Inﬂammatory Response
Syndrome (SIRS) (leukocytosis, hyperthermia, tachycardia
and tachypnea) can be present in both non-infectious and
infectious conditions and do not predict those subjects at
high risk for death. Readily available biomarkers can help
the practicing ID physician predict the likelihood of infection
and a poor outcome. Unexplained hypophosphatemia and
eosinopenia are common ﬁndings in the setting of bacterial
infection. Coagulation abnormalities including elevated D-
dimer, unexplained thrombocytopenia, Protein C deﬁciency
and prolonged prothrombin time (PT) are present to a
greater extent in patients with a deﬁnite focus of infection
or bacteremia than in those without. Protein C deﬁciency
occurs early in the setting of infection and the severity
predicts outcome. Lactic acidemia is present in the set-
ting of sepsis and the inability to clear it after appropriate
antibiotics and aggressive ﬂuid resuscitation predicts a poor
outcome.
Newer approved biomarkers for sepsis include serum pro-
calcitonin (PCT) and the Endotoxin Activity Assay (EAA).
Serum PCT has been shown to have better sensitivity and
speciﬁcity than the more commonly ordered C-reactive pro-
tein (CRP) in distinguishing SIRS from sepsis. PCT levels have
also been used to shorten the duration of antibiotic therapy.
The EAA assay is elevated in 85% of patients with severe sep-
sis and levels >0.6 are associated with the highest mortality.
A number of additional biomarkers for sepsis are actively
being investigated. In a clinical trial of a biomarker panel,
a score composed of neutrophil-gelatinase —associated
lipocalin (NGAL) in concert with IL-1 receptor antagonist
(IL-1ra) and Protein C had the highest diagnostic accu-
racy for severe sepsis. Levels of the biomarkers gelsolin,
angiopoietin 2 and inter-alpha inhibitors are associated with
sepsis severity and could potentially serve as theragnostics.
Sepsis-induced immunosuppression and propensity towards
secondary infection may be predicted by decreased mono-
cytic HLA-DR expression and reversed with treatment with
GM-CSF.
doi:10.1016/j.ijid.2010.02.2192
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Biomarkers for the Diagnosis of TB
J. Friedland
Imperial College London, London, United Kingdom
Many patients with tuberculosis are treated empirically
and failure to diagnose infection is a cause of morbidity and
mortality. Tuberculosis is a great mimic of other infectious
and non-infectious medical conditions. It may be difﬁcult
to distinguish active disease from latent infection from pre-
vious and even treated tuberculosis. There is also a major
problem in knowing if prophylactic therapy and new vac-
cination programmes are effective since the time course
of the development of active infection is measured over
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ecades. For all these reasons, there is great interest in the
evelopment of novel biomarkers in tuberculosis. To date,
he main biomarkers used in infection are skin tests which
ely on delayed hypersensitivity reactions and interferon
ssays. All these tests have limitations in terms of sensi-
ivity and ability to distinguish different forms of infection.
nitial interest in biomarkers focused on single markers such
s adenosine deaminase. It has become apparent that such
arkers do not provide sufﬁcient speciﬁcity. After brieﬂy
eviewing the topic, I shall focus on the current interest in
eﬁning multiple biomarkers for the diagnosis of tuberculo-
is. There has been interest in transciptomics, metabolomics
nd proteomics to deﬁne disease. Proteomics is particu-
arly attractive as there is the potential to develop tools
uch as dipsticks which are suitable for use in resource-
oor areas from such studies. Some data will be presented
rom our unpublished studies using proteomics to distin-
uish active and latent infection. An alternative, interesting
pproach that will be considered is the development of spe-
iﬁc immune proﬁles that reﬂect either latent or active
nfection with tuberculosis. The potential and current appli-
ation of biomarkers for tuberculosis is an exciting area and
eems likely to provide a future step-change in the diagnosis
f this global infection
oi:10.1016/j.ijid.2010.02.2193
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linical Utility of Biomarkers in Fungal Infection
. Patterson
University of Texas Health Science Center at San Antonio,
an Antonio, TX, USA
Biomarkers are important means for the diagnosis of
nvasive mycoses as cultures may not be positive even in
he setting of signiﬁcant infection. Furthermore, invasive
rocedures which may be necessary to establish deﬁnitive
vidence of infection are often reluctantly undertaken in
everely immunosuppressed patients. For some mycoses,
uch as Cryptococcus and Histoplasma, the detection of
irculating polysaccharide antigen has proven a very use-
ul target for both diagnosis and response to therapy. More
ecently biomarkers have been used to diagnose opportunis-
ic pathogens such as Candida and Aspergillus. A major focus
as been on measurement of Aspergillus galactomannan
rom serum and other body ﬂuids to establish a diagnosis of
nvasive aspergillosis. Serial measurements of galactoman-
an have been shown to correlate with progressive infection
r with successful outcomes of therapy in both pre-clinical
odels as well as in human infections. A number of fac-
ors signiﬁcantly reduce levels of circulating galactomannan
ncluding the use of mould-active antifungal therapy or pro-
hylaxis, immune status of the host and importantly extent
f infection. The test may not be positive despite invasive
nfection, particularly if localized to the lung or if anti-
ould agents are administered. PCR based-methods have
een developed for Aspergillus and Candida but the lack
f standardization and limited external validation have also
ampered utility of that approach. A non-speciﬁc fungal
iomarker, 1,3-beta, D-glucan, that it detected using a mod-
ﬁcation of the limulus lysate assay, is present in many
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ungi, including both yeasts and many moulds (Zygomycetes
eing a major exception). Detection of 1,3-beta, D-glucan
s approved for clinical use though cost and technical issues
ave limited its clinical acceptance for routine use. These
ethods are aimed at providing non-invasive and rapid
ethods for establishing a diagnosis of these often lethal
nfections.
oi:10.1016/j.ijid.2010.02.2194
urden of Plasmodium vivax malaria in Latin Amer-
ca (Invited Presentation)
4.001
pidemiology of P. vivax Malaria in the World and Latin
merica
.J. Rodriguez-Morales
Universidad Central de Venezuela, Caracas, DC, Venezuela
Morbidity and mortality burden of malaria, particu-
arly in children, represents a public health threat also in
hose countries from regions such as South East Asia and
atin America with moderate to low levels of transmis-
ion. Between them epidemiological patterns are similar,
ower malaria inoculation rates sustained with a predom-
nant prevalence of Plasmodium vivax infection. Malaria
ortality in these areas has been mainly attributed to P.
alciparum, but its direct and indirect burden has not well
eﬁned. These patterns are increasingly causing concern
n some countries. Globally, ∼250 million clinical episodes
ccur annually (2.7 in Latin America); most of these are
aused by infection with P. falciparum and P. vivax. Although
. falciparum is justiﬁably regarded as the greater menace
ecause of its high mortality, widespread antimalarial drugs
esistance and its dominance on Africa, malaria due to P.
ivax has also placed signiﬁcant burdens on health, longevity
nd general prosperity of large sections of the human pop-
lation. The debilitating impact of P. vivax malaria remains
igh, unacceptable and preventable for well over one billion
nhabitants of the planet. Complicated and even fatal cases
f malaria due to P. vivax have been increasingly reported
n the medical literature. Plasmodium vivax can cause both
equestration-related and non-sequestration-related com-
lications of severe malaria, including cerebral malaria,
enal failure, circulatory collapse, severe anemia, abnormal
leeding, ARDS and jaundice. In Latin America the burden of
ortality due to malaria, although decreasing, is still signiﬁ-
ant. Powerful antimalarial campaigns in the region directed
ainly to P. falciparum achieved a signiﬁcant reduction of
ortality in the last century. Evidence suggests that P. vivax
an imposes a signiﬁcant burden of mortality that may have
esulted from its interaction with other diseases and con-
itions. These and other epidemiological issues are herein
iscussed at a global level and focused in Latin America.
oi:10.1016/j.ijid.2010.02.2195
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olecular Epidemiology of P. vivax: tools for Malaria Con-
rol
. Escalante
Arizona State University, Tempe, AZ, USA
Plasmodium vivax is the most prevalent human malarial
arasite in several areas of Asia and South-Central America.
lthough Plasmodium genomics is improving our knowledge
f the organism’s complex biology, population-based inves-
igations are needed to explore the extent of the parasites’
enetic variation, how the observed variation is geograph-
cally distributed, and how such diversity affects or can
e used to assess the success of control measures. Unfor-
unately, the lack of suitable in vitro culturing methods
or P. vivax imposes the use of ﬁeld specimens for popu-
ation studies. Such circumstances have limited molecular
pidemiologic and genetic diversity studies to a handful of
ntigens and few genetic markers that could be considered
eutral, that is, that are not expected to be under natu-
al selection by the immune response or antimalarial drugs.
irst, I will discuss the emerging patterns on the genetic
iversity of P. vivax using neutral markers and explore
he value of comparative approaches to assess potential
ntigenic regions using closely related Plasmodium species
ound inmacaques. I will show an example with genes encod-
ng a well known antigen, AMA-1. Then, I will review the
urrent status of our knowledge on the genetic diversity of
his parasite in Latin-America. Overall, P. vivax populations
n the new world have low levels of genetic diversity and
ndergo clonal expansions. Such low genetic polymorphism
hould be considered while using genetic markers in epi-
emiologic investigations that aim to assess, for example,
he frequency of recrudescent infections or the reintroduc-
ion/expansion of the parasite in a given geographic area in
he context of control efforts.
oi:10.1016/j.ijid.2010.02.2196
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evere and complicated Malaria due to P. vivax
. Murillo
University of Miami, Miami, FL, USA
NO ABSTRACT RECEIVED
oi:10.1016/j.ijid.2010.02.2197
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reatment, Prophylaxis and Resistance in P. vivax Malaria
. Torres
Tropical Medicine Institute, Caracas, Venezuela
The burden of malaria caused by Plasmodium vivax
emains under-appreciated to a great extent, both in terms
f its clinical spectrum and incidence of disease. Con-
rol measures are hampered by both the emergence of
hloroquine (CQ) resistance and the presence of dormant
ypnozoite stages in the liver, which result in relapse infec-
